Shell Companies
Compare Stocks
5 / 10Stock Comparison
AFJK vs CANG vs BTBT vs MARA vs AUTL
Revenue, margins, valuation, and 5-year total return — side by side.
Auto - Dealerships
Financial - Capital Markets
Financial - Capital Markets
Biotechnology
AFJK vs CANG vs BTBT vs MARA vs AUTL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Shell Companies | Auto - Dealerships | Financial - Capital Markets | Financial - Capital Markets | Biotechnology |
| Market Cap | $261M | $250M | $589M | $4.83B | $410M |
| Revenue (TTM) | $0.00 | $3.46B | $164M | $907M | $51M |
| Net Income (TTM) | $1M | $-178M | $137M | $-1.31B | $-225M |
| Gross Margin | — | 13.6% | 61.9% | -47.7% | -309.4% |
| Operating Margin | — | 7.3% | 16.8% | -90.6% | -8.6% |
| Forward P/E | 251.0x | 5.7x | 9.2x | — | — |
| Total Debt | $2M | $170M | $14M | $3.65B | $53M |
| Cash & Equiv. | $3K | $1.29B | $95M | $547M | $227M |
AFJK vs CANG vs BTBT vs MARA vs AUTL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 24 | May 26 | Return |
|---|---|---|---|
| Aimei Health Techno… (AFJK) | 100 | 419.2 | +319.2% |
| Cango Inc. (CANG) | 100 | 90.2 | -9.8% |
| Bit Digital, Inc. (BTBT) | 100 | 69.3 | -30.7% |
| Marathon Digital Ho… (MARA) | 100 | 71.6 | -28.4% |
| Autolus Therapeutic… (AUTL) | 100 | 26.7 | -73.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AFJK vs CANG vs BTBT vs MARA vs AUTL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AFJK is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 320.4% 10Y total return vs CANG's -44.9%
- Beta 0.23 vs BTBT's 3.37
- +288.0% vs CANG's -73.7%
CANG ranks third and is worth considering specifically for income & stability.
- Dividend streak 5 yrs, beta 2.25
- Better valuation composite
BTBT carries the broadest edge in this set and is the clearest fit for bank quality.
- NIM 0.1% vs MARA's 0.1%
- 17.3% margin vs AUTL's -439.7%
- 0.3% yield; the other 4 pay no meaningful dividend
- 19.0% ROA vs AUTL's -34.0%, ROIC 6.5% vs -204.1%
Among these 5 stocks, MARA doesn't own a clear edge in any measured category.
AUTL is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 496.0%, EPS growth 27.5%, 3Y rev CAGR 88.7%
- Lower volatility, beta 1.95, Low D/E 12.3%, current ratio 10.88x
- Beta 1.95, current ratio 10.88x
- 496.0% revenue growth vs AFJK's -57.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 496.0% revenue growth vs AFJK's -57.2% | |
| Value | Better valuation composite | |
| Quality / Margins | 17.3% margin vs AUTL's -439.7% | |
| Stability / Safety | Beta 0.23 vs BTBT's 3.37 | |
| Dividends | 0.3% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +288.0% vs CANG's -73.7% | |
| Efficiency (ROA) | 19.0% ROA vs AUTL's -34.0%, ROIC 6.5% vs -204.1% |
AFJK vs CANG vs BTBT vs MARA vs AUTL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AFJK vs CANG vs BTBT vs MARA vs AUTL — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BTBT leads in 2 of 6 categories
CANG leads 2 • AFJK leads 1 • MARA leads 0 • AUTL leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
BTBT leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
CANG and AFJK operate at a comparable scale, with $3.5B and $0 in trailing revenue. BTBT is the more profitable business, keeping 17.3% of every revenue dollar as net income compared to AUTL's -4.4%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $3.5B | $164M | $907M | $51M |
| EBITDAEarnings before interest/tax | -$835,759 | $333M | $166M | $627M | -$427M |
| Net IncomeAfter-tax profit | $1M | -$178M | $137M | -$1.3B | -$225M |
| Free Cash FlowCash after capex | -$565,100 | $0 | -$448M | -$312M | -$278M |
| Gross MarginGross profit ÷ Revenue | — | +13.6% | +61.9% | -47.7% | -3.1% |
| Operating MarginEBIT ÷ Revenue | — | +7.3% | +16.8% | -90.6% | -8.6% |
| Net MarginNet income ÷ Revenue | — | -5.2% | +17.3% | -144.6% | -4.4% |
| FCF MarginFCF ÷ Revenue | — | -154.0% | -65.3% | -34.4% | -5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +58.3% | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -59.1% | +3.6% | +2.8% | -4.8% | +3.2% |
Valuation Metrics
CANG leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
At 5.7x trailing earnings, CANG trades at a 98% valuation discount to AFJK's 251.0x P/E. On an enterprise value basis, CANG's 3.1x EV/EBITDA is more attractive than BTBT's 8.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $261M | $250M | $589M | $4.8B | $410M |
| Enterprise ValueMkt cap + debt − cash | $263M | $85M | $508M | $7.9B | $235M |
| Trailing P/EPrice ÷ TTM EPS | 251.03x | 5.66x | 9.15x | -3.44x | -1.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 3.13x | 8.49x | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.12x | 3.60x | 5.32x | 40.47x |
| Price / BookPrice ÷ Book value/share | 21.48x | 0.42x | 0.56x | 1.30x | 0.96x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Profitability & Efficiency
BTBT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
BTBT delivers a 21.4% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-85 for AUTL. BTBT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to MARA's 1.05x. On the Piotroski fundamental quality scale (0–9), BTBT scores 6/9 vs AFJK's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +3.2% | -4.1% | +21.4% | -30.5% | -84.7% |
| ROA (TTM)Return on assets | +2.9% | -2.3% | +19.0% | -17.1% | -34.0% |
| ROICReturn on invested capital | -1.5% | +4.6% | +6.5% | -9.0% | -2.0% |
| ROCEReturn on capital employed | -2.0% | +4.5% | +8.5% | -12.1% | -45.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 6 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.25x | 0.04x | 0.03x | 1.05x | 0.12x |
| Net DebtTotal debt minus cash | $2M | -$1.1B | -$81M | $3.1B | -$175M |
| Cash & Equiv.Liquid assets | $2,929 | $1.3B | $95M | $547M | $227M |
| Total DebtShort + long-term debt | $2M | $170M | $14M | $3.6B | $53M |
| Interest CoverageEBIT ÷ Interest expense | — | -1.87x | — | 4.73x | -25.98x |
Total Returns (Dividends Reinvested)
AFJK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AFJK five years ago would be worth $42,044 today (with dividends reinvested), compared to $1,543 for BTBT. Over the past 12 months, AFJK leads with a +288.0% total return vs CANG's -73.7%. The 3-year compound annual growth rate (CAGR) favors AFJK at 61.4% vs BTBT's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -43.7% | -62.0% | -10.3% | +28.2% | -14.2% |
| 1-Year ReturnPast 12 months | +288.0% | -73.7% | -9.0% | -4.7% | +30.5% |
| 3-Year ReturnCumulative with dividends | +320.4% | +1.2% | -19.7% | +36.1% | -14.6% |
| 5-Year ReturnCumulative with dividends | +320.4% | -14.2% | -84.6% | -59.5% | -70.1% |
| 10-Year ReturnCumulative with dividends | +320.4% | -44.9% | -60.4% | -51.6% | -93.6% |
| CAGR (3Y)Annualised 3-year return | +61.4% | +0.4% | -7.1% | +10.8% | -5.1% |
Risk & Volatility
Evenly matched — AFJK and AUTL each lead in 1 of 2 comparable metrics.
Risk & Volatility
AFJK is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than BTBT's 3.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AUTL currently trades 59.4% from its 52-week high vs CANG's 18.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.23x | 2.25x | 3.37x | 3.11x | 1.95x |
| 52-Week HighHighest price in past year | $130.37 | $2.88 | $4.55 | $23.45 | $2.70 |
| 52-Week LowLowest price in past year | $6.75 | $0.33 | $1.25 | $6.66 | $1.15 |
| % of 52W HighCurrent price vs 52-week peak | +32.7% | +18.6% | +40.2% | +54.2% | +59.4% |
| RSI (14)Momentum oscillator 0–100 | 54.2 | 58.6 | 69.1 | 69.6 | 64.3 |
| Avg Volume (50D)Average daily shares traded | 21K | 1.3M | 18.5M | 47.6M | 1.6M |
Analyst Outlook
CANG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CANG as "Buy", BTBT as "Buy", MARA as "Buy", AUTL as "Buy". Consensus price targets imply 459.2% upside for CANG (target: $3) vs 27.0% for MARA (target: $16). BTBT is the only dividend payer here at 0.31% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $3.00 | $5.00 | $16.13 | $8.87 |
| # AnalystsCovering analysts | — | 2 | 2 | 19 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.3% | — | — |
| Dividend StreakConsecutive years of raises | — | 5 | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | $0.01 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.3% | 0.0% | +1.0% | 0.0% |
BTBT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CANG leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
AFJK vs CANG vs BTBT vs MARA vs AUTL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is AFJK or CANG or BTBT or MARA or AUTL a better buy right now?
For growth investors, Autolus Therapeutics plc (AUTL) is the stronger pick with 496.
0% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AFJK or CANG or BTBT or MARA or AUTL?
On trailing P/E, Cango Inc.
(CANG) is the cheapest at 5. 7x versus Aimei Health Technology Co. , Ltd at 251. 0x.
03Which is the better long-term investment — AFJK or CANG or BTBT or MARA or AUTL?
Over the past 5 years, Aimei Health Technology Co.
, Ltd (AFJK) delivered a total return of +320. 4%, compared to -84. 6% for Bit Digital, Inc. (BTBT). Over 10 years, the gap is even starker: AFJK returned +320. 4% versus AUTL's -93. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AFJK or CANG or BTBT or MARA or AUTL?
By beta (market sensitivity over 5 years), Aimei Health Technology Co.
, Ltd (AFJK) is the lower-risk stock at 0. 23β versus Bit Digital, Inc. 's 3. 37β — meaning BTBT is approximately 1343% more volatile than AFJK relative to the S&P 500. On balance sheet safety, Bit Digital, Inc. (BTBT) carries a lower debt/equity ratio of 3% versus 105% for Marathon Digital Holdings, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AFJK or CANG or BTBT or MARA or AUTL?
By revenue growth (latest reported year), Autolus Therapeutics plc (AUTL) is pulling ahead at 496.
0% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to -314. 5% for Marathon Digital Holdings, Inc.. Over a 3-year CAGR, AUTL leads at 88. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AFJK or CANG or BTBT or MARA or AUTL?
Cango Inc.
(CANG) is the more profitable company, earning 37. 3% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — BTBT leads at 61. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — AFJK or CANG or BTBT or MARA or AUTL?
In this comparison, BTBT (0.
3% yield) pays a dividend. AFJK, CANG, MARA, AUTL do not pay a meaningful dividend and should not be held primarily for income.
08Is AFJK or CANG or BTBT or MARA or AUTL better for a retirement portfolio?
For long-horizon retirement investors, Aimei Health Technology Co.
, Ltd (AFJK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +320. 4% 10Y return). Bit Digital, Inc. (BTBT) carries a higher beta of 3. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AFJK: +320. 4%, BTBT: -60. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AFJK and CANG and BTBT and MARA and AUTL?
These companies operate in different sectors (AFJK (Financial Services) and CANG (Consumer Cyclical) and BTBT (Financial Services) and MARA (Financial Services) and AUTL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: AFJK is a small-cap quality compounder stock; CANG is a small-cap deep-value stock; BTBT is a small-cap high-growth stock; MARA is a small-cap high-growth stock; AUTL is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.